Plant cell culture perfusion patents: who holds the claims and where filings are heading
Filings jumped 450% from 2021 to 2024, the fastest complete-year stretch in the dataset, before the usual 18-month publication lag understates 2025-2026. Filings rose from 2 in 2021 to 11 in 2024, a 450% increase over that three-year span, with a peak of 19 records in 2023. Treat 2025 and 2026 figures as undercounts until later publications catch up.
- 1AGRIGENETICS INC24
- 2PLURI BIOTECH LTD21
- 3ARBORGEN INC15
- 4MONSANTO TECHNOLOGY LLC14
- 5PROTALIX13
See the full plant cell culture perfusion culture analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
How many patents exist for plant cell culture perfusion methods?
This landscape identifies 285 published records that combine plant cell, tissue or suspension culture with perfusion-related operating parameters such as perfusion rate, bleed control, residence time or steady-state operation, filtered to IPC classes C12N5/04, A01H4/00 and C12M3/00. This is a scoped figure based on a specific search string, not a count of every patent that mentions plant cell culture. Broader or narrower keyword and classification choices would produce a different total, so treat 285 as the size of this defined dataset rather than the size of the field as a whole.
Who are the leading patent holders in plant cell culture perfusion technology?
The ranked list covers 100 assignees, with the leader holding 24 of the 285 records, fifth place holding 13, and tenth place holding 8. The top 5 assignees together account for 30.5% of all records and the top 10 account for 47.0%, meaning the field has a genuine leading cluster but is far from a single-company monopoly. Most of the remaining ranked entrants and unranked filers hold only one or a handful of records each, forming a long tail typical of an active but not yet consolidated technology area.
Is patent filing activity in plant cell culture perfusion growing?
Yes, based on complete-year data: filings rose from 2 in 2021 to 11 in 2024, a 450% increase, with the busiest single year so far being 2023 at 19 records. Because patent publication typically lags filing by around 18 months, the 2025 and 2026 figures in the raw trend are understated and will rise as later filings are published. Read the growth as continuing through the most recent complete year rather than assuming any apparent tapering in the newest years reflects a real slowdown.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Plant Cell Culture Perfusion Culture covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.